Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

BACKGROUND: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. METHODS: MEDI0680 was administered intravenously once every 2 weeks (Q2W) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Aung, Infante, Jeffrey, Goel, Sanjay, Burris, Howard, Black, Chelsea, Marshall, Shannon, Achour, Ikbel, Barbee, Susannah, May, Rena, Morehouse, Chris, Pollizzi, Kristen, Song, Xuyang, Steele, Keith, Elgeioushi, Nairouz, Walcott, Farzana, Karakunnel, Joyson, LoRusso, Patricia, Weise, Amy, Eder, Joseph, Curti, Brendan, Oberst, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704567/
https://www.ncbi.nlm.nih.gov/pubmed/31439037
http://dx.doi.org/10.1186/s40425-019-0665-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704567/
https://www.ncbi.nlm.nih.gov/pubmed/31439037
http://dx.doi.org/10.1186/s40425-019-0665-2

Ejemplares similares